Prosecution Insights
Last updated: April 19, 2026
Application No. 18/262,712

TRIAZINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME

Non-Final OA §102§112
Filed
Jul 24, 2023
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Athos Therapeutics, Inc.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
3y 1m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
83 granted / 109 resolved
+16.1% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
35 currently pending
Career history
144
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 109 resolved cases

Office Action

§102 §112
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-3, 8, 10-13, 18-19, 21-22, 29-30, 35-36, 40, and 43-45 are pending. Claims 2-3, 18, 21, 35-36, 40, and 44-45 are withdrawn. Claims 1, 8, 10-13, 19, 22, and 30 are rejected. Claims 29 and 43 are objected to. Information Disclosure Statements The Information Disclosure Statements (IDS’s) from 7/24/2023 and 5/22/2025 were considered by the Examiner. Election/Restrictions Applicant’s election without traverse of Group I and the species: PNG media_image1.png 153 257 media_image1.png Greyscale , in the reply filed on 12/23/2025 is acknowledged. Claims 1, 8, 10-13, 19, 22, 29, 30 and 43 embrace Applicant’s elected species and are therefore under Examination. The elected species is allowable. As per MPEP 803.02, “Following election, the Markush claim will be examined fully with respect to the elected species and further to the extent necessary to determine patentability.” Non-elected species have been discovered incidental to the search and are presented below in the interest of compact prosecution. Additionally, claims 1, 8, 10-13, 19, 22, 29, 30 and 43 have been searched in full. Claims 22, 29, 30, and 43 have been found free of the art. Claims 2-3, 18, 21, 35-36, 40, and 44-45 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claim Objections Claim 43 is objected to because on p. 12, Compound 102 and Compound 105 have periods after them. Examiner requests the removal of said periods to overcome this objection. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 10, 11, 12, 19, 22 and 30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1, line 4, recites “-N-“ as an option for “L”. Nitrogen is trivalent and as written: “-N-“ only indicates nitrogen having two connections. It is unclear what Applicant intended to bond to nitrogen in the available third location. Examiner recommends deleting this option for “L”. Claim 1, line 5, recites “- -C(=O)-“ as an option for “L”. It is unclear what Applicant intended from the dashed line/double dash. For example, the instant specification paragraph [0115] recites the following (arrow added by Examiner): PNG media_image2.png 137 758 media_image2.png Greyscale , wherein no options have the double dash. Examiner recommends clarifying if one of the dashes was intended to be omitted or to be another atom. Claims 10, 11, 12, 19, and 22 are rejected for depending on an indefinite claim (instant claim 1) and failing to remedy its deficiencies. Claim 11 recites the limitation "[t]he compound of claim 9". There is insufficient antecedent basis for this limitation in the claim because instant claim 9 has been cancelled. Examiner recommends correcting dependency of claim 11 to remedy the lack of antecedent basis. In the interest of compact prosecution and in light of prior art, Examiner has interpreted claim 11 as depending from pending claim 1. Claim 12 recites the limitation "[t]he compound of claim 9". There is insufficient antecedent basis for this limitation in the claim because instant claim 9 has been cancelled. Examiner recommends correcting dependency of claim 12 to remedy the lack of antecedent basis. In the interest of compact prosecution and in light of prior art, Examiner has interpreted claim 12 as depending from pending claim 8. Claim 30 is rejected because it refers to “Compound 4, 5, 6, 8, 26, 91, and 96” of the instant specification. A claim should particularly point out and distinctly claim the subject matter which the applicant regards as his invention and, under modern claim practice, stand alone to define the invention. MPEP 2173.05(s) states “Where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table “is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant’s convenience.” Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993)”. Examiner recommends inserting the actual structures of compounds 4, 5, 6, 8, 26, 91, and 96 into the body of claim 30 to overcome this rejection. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 12 rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 12 incorrectly depends from claim 9, but as described supra, Examiner is examining as though dependent on claim 8. In lines 2-3 of claim 12, “3 to 6 membered heteroaryl” is listed as an option for “A1”. This definition does not correctly depend nor further limit the “A1” definition in independent claim 1, which allows for “A1” to be “5-12 membered heteroaryl”. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 30 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 30 depends from claim 29, wherein claim 29 recites a compound of the structure of Formula (Ia): PNG media_image3.png 105 153 media_image3.png Greyscale . Claim 30 includes compound 26 (arrow added by Examiner): PNG media_image4.png 151 179 media_image4.png Greyscale , wherein compound 26 does not correctly depend from instant Formula (Ia). Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (1 of 4) Claims 1, 11, and 19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 1469290-28-5 (which entered the STN database on 11/4/2013). Regarding instant claims 1, 11 and 19, CAS Registry No. 1469290-28-5 is drawn to the following structure: PNG media_image5.png 221 314 media_image5.png Greyscale , which is embraced by a compound of instant Formula (I): PNG media_image6.png 106 199 media_image6.png Greyscale , wherein L = -NH2, R1= H; Aa, Ab, and A1= not present; A2 = pyrazole, PNG media_image7.png 73 76 media_image7.png Greyscale ; Ac is not present; A3 = substituted C6 aryl: PNG media_image8.png 109 118 media_image8.png Greyscale . (2 of 4) Claim(s) 1, 8 and 11-12 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 404874-28-8 (which entered the STN database on 4/9/2002-art used for restriction mailed on 10/23/2025). Regarding instant claims 1, 8, and 11-12, CAS Registry No. 404874-28-8 is drawn to the following structure: PNG media_image9.png 254 272 media_image9.png Greyscale , which is embraced by a compound of instant Formula (I): PNG media_image6.png 106 199 media_image6.png Greyscale , wherein Ac = not present; A3 = substituted C6 aryl: PNG media_image10.png 119 134 media_image10.png Greyscale ; A2 = pyridine; L = NH, R1 = H; Aa, Ab = not present; A1 = substituted 5 membered heteroaryl: PNG media_image11.png 91 102 media_image11.png Greyscale . (3 of 4) Claim(s) 1 and 10-11 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 3599-73-3 (which entered the STN database on 11/16/1984). Regarding instant claims 1 and 10-11, CAS Registry No. 3599-73-3 is drawn to the following structure: PNG media_image12.png 200 210 media_image12.png Greyscale , which is embraced by a compound of instant Formula (I): PNG media_image6.png 106 199 media_image6.png Greyscale , wherein L = single bond; Aa = substituted C1 alkylene: PNG media_image13.png 70 119 media_image13.png Greyscale ; Ab and A1 = not present; A2 = pyridine; A3 = substituted C1 alkyl: PNG media_image14.png 97 82 media_image14.png Greyscale . (4 of 4) Claim(s) 1, 8, 10, 11, 12 and 13 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 1253574-48-9 (which entered the STN database on 11/18/2010). Regarding instant claims 1, 8, 10, 11, 12 and 13, CAS Registry No. 1253574-48-9 is drawn to the following structure: PNG media_image15.png 202 305 media_image15.png Greyscale , which is embraced by a compound of instant Formula (I): PNG media_image6.png 106 199 media_image6.png Greyscale , wherein L = -NH-; Aa = C2 alkylene; Ab= not present; A1 = C1 alkoxy; “L, Aa, Ab, and A1 together” = PNG media_image16.png 58 131 media_image16.png Greyscale ; Ac = not present; A3 = C1 alkyl; A2 = PNG media_image17.png 156 81 media_image17.png Greyscale (paragraph [0014] of the instant specification allows for A2 to be substituted with halogen). Closest Prior Art The closest prior art to claim 22 is CAS Registry No. 331451-11-7 (which entered the STN database on 4/16/2001). CAS Registry No. 331451-11-7 is drawn to the following structure (arrow added by Examiner): PNG media_image18.png 244 330 media_image18.png Greyscale . The prior art compound differs in the location of the added arrow, wherein A2, as claimed may be pyrazole and the prior art compound has a bi-substituted tautomer. The instant claims are not drawn to tautomers of a compound of instant Formula (I). It would not have been obvious to a PHOSITA (nor anticipated) to arrive at a bi-substituted tautomer of the prior art to satisfy the instant claims. Additionally, prior to the effective filing date of the instant claims, the prior art compound shown supra was not taught as a JMJD3 inhibitor, as are the instant compounds (disclosed in the instant specification, para. [0004]). The closest prior art to instant claims 29, 30 and 43 is CAS Registry No. 1391925-44-2 (which entered the STN database on 9/20/2012). Regarding instant claim 29, CAS Registry No. 1391925-44-2 is drawn to the following structure: PNG media_image19.png 261 322 media_image19.png Greyscale , which is similar to a compound of instant Formula (Ia): PNG media_image20.png 111 175 media_image20.png Greyscale , wherein L = -NH-; Aa = C1 alkylene; Ab = -C(=O)-; A1 = hydroxyl; A2 = PNG media_image21.png 103 117 media_image21.png Greyscale (paragraph [0014] of the instant specification allows for A2 to be substituted with halogen). The prior art differs from instant claim 29 in the location of A3, wherein the instant claims do not allow for the prior art’s: PNG media_image22.png 93 76 media_image22.png Greyscale . Regarding instant claims 30 and 43, which are drawn to a variety of species free of the prior art, the prior art compound shown directly supra is also the closest prior art. Allowable Subject Matter Claim 29 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. See above description of closest prior art for claim 29. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/ Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Jul 24, 2023
Application Filed
Jan 27, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600716
COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12600715
SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS
2y 5m to grant Granted Apr 14, 2026
Patent 12599560
LIPIDS AND LIPID NANOPARTICLE FORMULATIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12582637
NOVEL TOPICAL FORMULATION FOR INTRADERMAL APPLICATION AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12577213
DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+33.6%)
3y 1m
Median Time to Grant
Low
PTA Risk
Based on 109 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month